Homepage Top Section2

Based in London, Nightstar is engaged in the development and commercialization of one-time treatments for patients with inherited retinal diseases. The company is mainly focused on the development

The regulator has adopted positive opinion and recommended conditional marketing authorization for Lorviqua as monotherapy treatment for adult patients with ALK-positive advanced NSCLC whose disease has progressed after

The clinical trial, which enrolled 41 patients with Parkinson’s Disease, was funded by Parkinson’s UK with support from The Cure Parkinson’s Trust and in association with the North

Danaher seeks to help its customers solve complex challenges and enhance quality of life across the world. GE Biopharma offers instruments, consumables, and software to facilitate research, discovery,

Through the transaction, Ipsen will acquire Clementia’s key late-stage clinical asset palovarotene, which is an investigational retinoic acid receptor gamma (RARγ) selective agonist. Palovarotene is being developed for

As per terms of the deal, Merck’s subsidiary will pay $5.85 per share to purchase all outstanding shares of Immune Design. Immune Design has next-generation in vivo approaches,

Sandoz will market the authorized generic version of Suboxone on behalf of Indivior in the country. Indivior said its decision is based on the market impact expected from

Entrectinib has been granted priority review for the treatment of neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced or metastatic solid tumors in adult and paediatric patients. The

Additional work conducted on a drug exposure-response analysis showed a statistically significant response of BNC210 in treatment of PTSD symptoms, as measured by Clinician-Administered PTSD Scale (CAPS-5) at